New Drug Approved for Alcohol Use Disorder — First in 20 Years
Despite the hopeful framing of this headline, no new drug has actually been approved by the FDA for alcohol use disorder as of early 2026.
Category Aphasia
New Enzyme Replacement Therapy Approved for Ultra-Rare Condition
On February 23, 2026, the FDA granted accelerated approval to Loargys (pegzilarginase-nbln), the first and only injectable enzyme replacement therapy for...
New Oral GLP-1 Drug May Replace Injections for Weight Loss — Study Shows
A daily pill may soon offer the same weight loss benefits as the injectable GLP-1 drugs that have transformed obesity treatment over the past few years.
What Happens to Your Body When You Stop a Weight Loss Injection
When you stop a weight loss injection like semaglutide or tirzepatide, your body begins reversing course almost immediately.
The Weight Loss Drug That Works on Your Brain — Not Your Stomach
The newest class of weight loss drugs — GLP-1 receptor agonists like semaglutide, and the next-generation compounds racing through clinical trials — work...
The New FDA-Approved Weight Loss Pill — No Injection Required
On December 22, 2025, the FDA approved the first oral GLP-1 receptor agonist for weight management — a pill form of Wegovy (semaglutide) made by Novo...
Tirzepatide vs. Semaglutide: The Weight Loss Drug Showdown
Tirzepatide beats semaglutide on raw weight loss numbers, and it is not particularly close. In the landmark SURMOUNT-5 trial published in the New England...
Why Oncologists Are Excited About CAR-T Therapy in 2025
Oncologists are excited about CAR-T therapy in 2025 because the technology has crossed a critical threshold — moving from a last-resort experimental...
Why Chemotherapy Hair Loss Is Temporary for Most — But Not All
For the vast majority of cancer patients, chemotherapy-related hair loss is reversible. Hair typically begins regrowing six to eight weeks after the final...
What is the prognosis for primary progressive aphasia
The prognosis for primary progressive aphasia is sobering but highly variable. On average, people with PPA survive 7 to 12 years from symptom onset,...